Brief: Poxel H1 Revenue Down At 6.4 Million Euros

Poxel SA

21/07/2020 16:55

July 21 (Reuters) - Poxel SA  POXEL.PA :
    * PROVIDES CORPORATE UPDATE AND REPORTS CASH AND REVENUE FOR
THE
SECOND QUARTER AND FIRST HALF 2020
    * AS OF JUNE 30, 2020, CASH AND CASH EQUIVALENTS WERE EUR
46.0
MILLION (USD 51.5 MILLION), AS COMPARED TO EUR 37.2 MILLION (USD
41.8 MILLION) AT DECEMBER 31, 2019
    * REVENUES OF EUR 6.4 MILLION FOR THE SIX MONTHS ENDED JUNE
30,
2020, AS COMPARED TO EUR 23.2 MILLION DURING THE CORRESPONDING
PERIOD IN 2019 (HISTORICAL)
    * COMPLETED A CAPITAL RAISE OF EUR 17.7 MILLION (USD 19.4
MILLION)
TO ACCELERATE DEVELOPMENT OF PXL770 AND PXL065 IN NASH
    * PXL770, A FIRST-IN-CLASS DIRECT AMPK ACTIVATOR PRODUCED
POSITIVE
RESULTS IN A PHARMACOKINETIC (PK) / PHARMACODYNAMIC (PD) TRIAL
IN LIKELY-NASH PATIENTS
    * IMEGLIMIN JAPANESE NEW DRUG APPLICATION (J-NDA) SUBMISSION
FOR
THE TREATMENT OF TYPE 2 DIABETES IS ANTICIPATED IN THE THIRD
QUARTER OF 2020 WITH A TARGET LAUNCH IN 2021
    * PXL770 PHASE 2A STUDY RESULTS IN APPROXIMATELY 100
LIKELY-NASH
PATIENTS ARE EXPECTED IN LATE THIRD QUARTER 2020
    * PXL770 PRECLINICAL RESULTS PRODUCED ADDITIVE BENEFITS IN A
NASH
MODEL WHEN COMBINED WITH OTHER LATE-STAGE AGENTS IN DEVELOPMENT

Source text for Eikon:  ID:nBw2KGCtDa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))